Amyloid-β and Tau at the Crossroads of Alzheimer's Disease.

[1]  Manoj Kumar,et al.  INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.

[2]  Bin Zhang,et al.  Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation , 2017, Nature Medicine.

[3]  Daniel R. Schonhaut,et al.  Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease , 2017, Brain : a journal of neurology.

[4]  A. Fagan,et al.  ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy , 2017, Nature.

[5]  Matthew P Frosch,et al.  Enhanced Tau Aggregation in the Presence of Amyloid β. , 2017, The American journal of pathology.

[6]  M. Weiner,et al.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons , 2017, JAMA.

[7]  John L. Robinson,et al.  Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases , 2017, Journal of neuropathology and experimental neurology.

[8]  J. Trojanowski,et al.  Unique pathological tau conformers from Alzheimer’s brains transmit tau pathology in nontransgenic mice , 2016, The Journal of experimental medicine.

[9]  J. Grutzendler,et al.  TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy , 2016, Neuron.

[10]  N. Kanaan,et al.  Pathological conformations involving the amino terminus of tau occur early in Alzheimer’s disease and are differentially detected by monoclonal antibodies , 2016, Neurobiology of Disease.

[11]  J. Grutzendler,et al.  TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy , 2016, Neuron.

[12]  Yi Su,et al.  Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease , 2016, Science Translational Medicine.

[13]  Ben A. Barres,et al.  Complement and microglia mediate early synapse loss in Alzheimer mouse models , 2016, Science.

[14]  D. Holtzman,et al.  TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques , 2016, The Journal of experimental medicine.

[15]  M. Jorge Cardoso,et al.  Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis , 2016, Neurobiology of Aging.

[16]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[17]  Jennifer Luebke,et al.  Depletion of microglia and inhibition of exosome synthesis halt tau propagation , 2015, Nature Neuroscience.

[18]  Guixiang Xu,et al.  Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. , 2015, Brain : a journal of neurology.

[19]  D. Holtzman,et al.  TREM2 lipid sensing sustains microglia response in an Alzheimer’s disease model , 2015, Cell.

[20]  G. Taglialatela,et al.  NFκB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer’s Disease , 2015, Neuron.

[21]  Y. Xiong,et al.  Pittsburgh compound B retention and progression of cognitive status – a meta‐analysis , 2014, European journal of neurology.

[22]  D. Holtzman,et al.  Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2 , 2014, Molecular Neurodegeneration.

[23]  Philip S. Insel,et al.  Emerging β-amyloid pathology and accelerated cortical atrophy. , 2014, JAMA neurology.

[24]  George Jewell,et al.  Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study , 2014, Molecular Psychiatry.

[25]  E. Mandelkow,et al.  Amyloid‐β oligomers induce synaptic damage via Tau‐dependent microtubule severing by TTLL6 and spastin , 2013, The EMBO journal.

[26]  A. Fagan,et al.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study , 2013, The Lancet Neurology.

[27]  Jurgen Fripp,et al.  Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. , 2013, JAMA neurology.

[28]  A. Fagan,et al.  Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later , 2013, Alzheimer's & Dementia.

[29]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[30]  M. Jorge Cardoso,et al.  Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials , 2013, PloS one.

[31]  Keith A. Johnson,et al.  Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals , 2013, Neurobiology of Aging.

[32]  J. Trojanowski,et al.  Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy , 2013, The Journal of Neuroscience.

[33]  C. Rowe,et al.  18F-florbetaben Aβ imaging in mild cognitive impairment , 2013, Alzheimer's Research & Therapy.

[34]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[35]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[36]  V. Laporte,et al.  Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. , 2012, The American journal of pathology.

[37]  Keith A. Johnson,et al.  Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline , 2012, Neurology.

[38]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[39]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[40]  B. Barres,et al.  Genomic Analysis of Reactive Astrogliosis , 2012, The Journal of Neuroscience.

[41]  A. Andreadis,et al.  Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport , 2012, Neurobiology of Aging.

[42]  C. Rowe,et al.  Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition , 2012, Neurology.

[43]  C. Jack,et al.  Evidence for ordering of Alzheimer disease biomarkers. , 2011, Archives of neurology.

[44]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[45]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[46]  M. Weiner,et al.  The dynamics of cortical and hippocampal atrophy in Alzheimer disease. , 2011, Archives of neurology.

[47]  P. Bosco,et al.  APOE and Alzheimer disease: a major gene with semi-dominant inheritance , 2011, Molecular Psychiatry.

[48]  Julie R. Leitz,et al.  Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation , 2011, The Journal of Neuroscience.

[49]  H. Braak,et al.  The pathological process underlying Alzheimer’s disease in individuals under thirty , 2011, Acta Neuropathologica.

[50]  R. Ransohoff,et al.  Regulation of Tau Pathology by the Microglial Fractalkine Receptor , 2010, Neuron.

[51]  John Q Trojanowski,et al.  A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. , 2010, The American journal of pathology.

[52]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[53]  C. Rowe,et al.  Relationship between atrophy and β‐amyloid deposition in Alzheimer disease , 2010, Annals of neurology.

[54]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[55]  A. Fagan,et al.  Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.

[56]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[57]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[58]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[59]  H. Braak,et al.  Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship , 2009, Journal of neuropathology and experimental neurology.

[60]  M. Staufenbiel,et al.  Induction of Tau Pathology by Intracerebral Infusion of Amyloid-β-Containing Brain Extract and by Amyloid-β Deposition in APP × Tau Transgenic Mice , 2007 .

[61]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[62]  L. Piccio,et al.  Blockade of TREM‐2 exacerbates experimental autoimmune encephalomyelitis , 2007, European journal of immunology.

[63]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[64]  A. Erisir,et al.  Tau-dependent microtubule disassembly initiated by prefibrillar β-amyloid , 2006, The Journal of cell biology.

[65]  Paul Edison,et al.  Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.

[66]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[67]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[68]  H. Neumann,et al.  Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2 , 2005, The Journal of experimental medicine.

[69]  J. Wegiel,et al.  Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease , 2004, Neurobiology of Aging.

[70]  Wei Xu,et al.  aph-1 and pen-2 Are Required for Notch Pathway Signaling, γ-Secretase Cleavage of βAPP, and Presenilin Protein Accumulation , 2002 .

[71]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[72]  M. Vitek,et al.  Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[73]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[74]  A. Fagan,et al.  Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease , 2002, Neurobiology of Disease.

[75]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[76]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[77]  S. Younkin,et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.

[78]  J. Vickers,et al.  The morphological phenotype of β-amyloid plaques and associated neuritic changes in Alzheimer’s disease , 2001, Neuroscience.

[79]  J. Kuret,et al.  C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. , 2000, Journal of cell science.

[80]  Ruedi Aebersold,et al.  Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing , 2000, Nature.

[81]  A. Fagan,et al.  Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model , 2000, Annals of neurology.

[82]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[83]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[84]  Konrad Maurer,et al.  Auguste D and Alzheimer's disease , 1997, The Lancet.

[85]  P. Baeuerle,et al.  Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease , 1997 .

[86]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[87]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[88]  J. Morris,et al.  Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[89]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[90]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[91]  B. Yankner,et al.  β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding , 1995, Neuron.

[92]  J. Trojanowski,et al.  Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau , 1994, Neuron.

[93]  J. Troncoso,et al.  Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease , 1994, The Lancet.

[94]  P. Cohen,et al.  Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. , 1994, The Biochemical journal.

[95]  D. Selkoe,et al.  Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. , 1994, The Journal of biological chemistry.

[96]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[97]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[98]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[99]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[100]  K. Imahori,et al.  τ Protein Kinase II Is Involved in the Regulation of the Normal Phosphorylation State of τ Protein , 1993 .

[101]  S. Younkin,et al.  Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. , 1993, Science.

[102]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[103]  Bradley T. Hyman,et al.  Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease , 1992, Neurology.

[104]  B. Winblad,et al.  A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid , 1992, Nature Genetics.

[105]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[106]  E. Mandelkow,et al.  The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region. , 1992, The EMBO journal.

[107]  J. Hardy,et al.  Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene , 1991, Nature.

[108]  B. Ghetti,et al.  A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. , 1991, Science.

[109]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[110]  M. Tabaton,et al.  Neuropil threads of Alzheimer's disease show a marked alteration of the normal cytoskeleton , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[111]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[112]  J. Hardy,et al.  Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). , 1990, Science.

[113]  I. Lieberburg,et al.  Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. , 1990, Science.

[114]  R. S. Williams,et al.  A prospective study of Alzheimer disease in Down syndrome. , 1989, Archives of neurology.

[115]  J. Trojanowski,et al.  Intraneuronal and extracellular neurofibrillary tangles exhibit mutually exclusive cytoskeletal antigens , 1988, Annals of neurology.

[116]  H. Braak,et al.  Neuropil Threads Occur in Dendrites of Tangle—Bearing Nerve Cells , 1988, Neuropathology and applied neurobiology.

[117]  D. Selkoe,et al.  Tau Epitopes are Incorporated into a Range of Lesions in Alzheimer's Disease , 1987, Journal of neuropathology and experimental neurology.

[118]  M. Lerman,et al.  Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. , 1987, Science.

[119]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[120]  H. Braak,et al.  Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: A third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques , 1986, Neuroscience Letters.

[121]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[122]  H. Wiśniewski,et al.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome , 1985, Annals of neurology.

[123]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[124]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[125]  M. Kirschner,et al.  Tubulin requires tau for growth onto microtubule initiating sites. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[126]  M. Kidd.  Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease , 1963, Nature.

[127]  Thomas Wisniewski,et al.  Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy , 2015, Acta Neuropathologica.

[128]  B. Hyman,et al.  Neuropathology of Alzheimer's disease. , 2008, Handbook of clinical neurology.

[129]  D. Campion,et al.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.

[130]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[131]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[132]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[133]  G. Glenner,et al.  The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. , 1984, Applied pathology.